BSE Live
Mar 06, 09:00Prev. Close
8596.15
Open Price
0.00
Bid Price (Qty.)
8500.00 (1)
Offer Price (Qty.)
8750.00 (1)
NSE Live
Mar 06, 09:00Prev. Close
8601.00
Open Price
8551.00
Bid Price (Qty.)
8551.00 (2)
Offer Price (Qty.)
8620.00 (2)
| Profit & Loss account of AstraZeneca Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 831.77 | 728.24 | 557.60 | 535.40 | 532.67 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.99 | 4.95 | 6.21 | |
| Revenue From Operations [Net] | 831.77 | 728.24 | 556.61 | 530.45 | 526.46 | |
| Total Operating Revenues | 831.81 | 728.29 | 571.00 | 543.71 | 563.73 | |
| Other Income | 12.99 | 16.29 | 12.25 | 14.39 | 6.77 | |
| Total Revenue | 844.80 | 744.58 | 583.25 | 558.10 | 570.50 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 70.21 | 62.67 | 27.88 | 14.01 | 34.76 | |
| Purchase Of Stock-In Trade | 274.23 | 169.84 | 204.21 | 141.95 | 158.89 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -39.21 | -1.38 | -51.00 | 17.98 | 5.42 | |
| Employee Benefit Expenses | 216.70 | 197.40 | 153.53 | 162.04 | 169.35 | |
| Finance Costs | 1.14 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation And Amortisation Expenses | 18.58 | 14.92 | 14.74 | 15.83 | 17.43 | |
| Other Expenses | 189.18 | 228.46 | 190.09 | 170.79 | 178.91 | |
| Total Expenses | 730.83 | 671.91 | 539.45 | 522.60 | 564.74 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 113.97 | 72.67 | 43.80 | 35.50 | 5.76 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 113.97 | 72.67 | 43.80 | 35.50 | 5.76 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 31.51 | 16.68 | 9.00 | 8.76 | 0.50 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 10.25 | 1.54 | 8.89 | 6.69 | 0.00 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 41.76 | 18.22 | 17.89 | 15.45 | 0.50 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 72.21 | 54.45 | 25.91 | 20.05 | 5.26 | |
| Profit/Loss From Continuing Operations | 72.21 | 54.45 | 25.91 | 20.05 | 5.26 | |
| Profit/Loss For The Period | 72.21 | 54.45 | 25.91 | 20.05 | 5.26 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | |
| Diluted EPS (Rs.) | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 21.66 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 13.10 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 2.59 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 2.50 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.51 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 50.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12.02.2026
01.02.2026
12.11.2025
AstraZeneca Standalone September 2025 Net Sales at Rs 559.09 crore, up 37.03% Y-o-Y
10.11.2025
12.11.2025
AstraZeneca Standalone September 2025 Net Sales at Rs 559.09 crore, up 37.03% Y-o-Y
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
17.02.2025
AstraZeneca Standalone December 2024 Net Sales at Rs 440.29 crore, up 43.98% Y-o-Y
21.11.2024
AstraZeneca Standalone September 2024 Net Sales at Rs 408.00 crore, up 31.16% Y-o-Y